Cyclacel Pharmaceuticals Inc CYCC:NASDAQ

RT Quote | NASDAQ | USD
Last | 04/19/21 EDT
6.48quote price arrow down-0.04 (-0.61%)
Volume
97,166
52 week range
3.12 - 19.25

...

Loading . . .
  • Open6.52
  • Day High6.70
  • Day Low6.34
  • Prev Close6.48
  • 52 Week High19.25
  • 52 Week High Date04/20/20
  • 52 Week Low3.12
  • 52 Week Low Date10/28/20

Key Stats

  • Market Cap52.16M
  • Shares Out8.05M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta1.19
  • YTD % Change-17.03

KEY STATS

  • Open6.52
  • Day High6.70
  • Day Low6.34
  • Prev Close6.48
  • 52 Week High19.25
  • 52 Week High Date04/20/20
  • 52 Week Low3.12
  • 52 Week Low Date10/28/20
  • Market Cap52.16M
  • Shares Out8.05M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta1.19
  • YTD % Change-17.03

RATIOS/PROFITABILITY

  • EPS (TTM)-32.47
  • P/E (TTM)-0.20
  • Fwd P/E (NTM)-2.90
  • EBITDA (MRQ)-10.616M
  • ROE (MRQ)-55.26%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-5,029.33%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/14/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Cyclacel Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate...
David U'Prichard Ph.D.
Chairman
Christopher Henney Ph.D.
Vice Chairman
Spiro Rombotis
President
Paul McBarron
Chief Financial Officer
Address
200 Connell Dr Ste 1500
Berkeley Heights, NJ
07922-2811
United States

Top Peers

SYMBOLLASTCHG%CHG
EARS
Auris Medical Holding Ltd
3.43-0.07-2.00%
IDRA
Idera Pharmaceuticals Inc
1.02-0.08-7.27%
VIRX
Viracta Therapeutics Inc
7.55-0.45-5.62%
BLPH
Bellerophon Therapeutics Inc
4.37-0.09-2.02%
NNVC
NanoViricides Inc
3.99-0.12-2.92%